BioCentury
ARTICLE | Company News

Jennerex Biotherapeutics, SillaJen deal

March 24, 2014 7:00 AM UTC

CRO SillaJen completed its acquisition of cancer company Jennerex for up to $150 million in cash in an undisclosed upfront payment, plus milestones. By the end of 1Q15, SillaJen plans to begin a Phase...